Tuberculosis remains a major infectious cause of morbidity and mortality worldwide. Current antibiotic regimens, constructed prior to the development of modern pharmacokinetic–pharmacodynamic (PK–PD) tools, are based on incomplete understanding of exposure–response relationships in drug susceptible and multidrug resistant tuberculosis. Preclinical and population PK data suggest that clinical PK–PD studies may enable therapeutic drug monitoring for some agents and revised dosing for others. Future clinical PK–PD challenges include: incorporation of PK methods to assay free concentrations for all active metabolites; selection of appropriate early outcome measures which reflect therapeutic response; elucidation of genetic contributors to interindividual PK variability; conduct of targeted studies on special populations (including children); and measurement of PK–PD parameters at the site of disease.

First draft submitted: 12 January 2017; Accepted for publication: 16 May 2017; Published online: 12 July 2017

Keywords: clinical trials • compartmental pharmacokinetics • multidrug-resistant tuberculosis • pharmacogenetics • pharmacokinetics–pharmacodynamics • therapeutic drug monitoring • tuberculosis

In 2015 there were an estimated 10.4 million new tuberculosis (TB) cases, 1.4 million TB deaths in HIV uninfected patients and 0.4 million TB deaths among people living with HIV [1]. Despite significant progress since the 1990s, the WHO End TB Strategy aim of ‘a world free of TB’ by 2035 will not be achieved without scientific advances to improve antituberculous chemotherapy. To evaluate the role of clinical pharmacokinetic (PK) and pharmacodynamic (PD) studies in reaching this target it is necessary to understand the problems with current treatment and review desirable attributes for new antibiotic regimens.

Current problems & priority goals for TB therapeutics

Between 1946 and 1986, a series of multicenter clinical trials conducted by the British Medical Research Council and others demonstrated that patients suffering from drug-susceptible (DS)-TB, caused by Mycobacterium tuberculosis (MtB) bacteria in the absence of antimicrobial resistance, could be cured by a 6-month course of combination therapy (2 months of rifampicin, isoniazid, pyrazinamide and ethambutol followed by 4 months of rifampicin and isoniazid) with a 5–8% post-treatment relapse rate at 2 years [2]. These data informed the design of current ‘short-course’ treatment regimens and TB seemed destined to become a disease of the past.

However, the late 20th century saw a dramatic TB resurgence with the major burden of illness in low and middle income countries. Particularly in sub-Saharan Africa, the co-existent HIV pandemic catalyzed a sharp rise in TB incidence, making adherence of
every patient to 6 months of chemotherapy impossible for public health services to support [3]. To exacerbate matters, antituberculous drugs can cause significant toxicity and some components (principally rifampicin) are associated with problematic drug–drug interactions when combined with antiretroviral therapy [4]. Poor adherence and complex polypharmacy leads to unfavorable outcomes and it has become apparent that shorter TB treatment is needed [5]. Mathematical modeling suggests that shortening effective chemotherapy to 2 months could reduce TB incidence by 20%, and mortality by 25%. More modest gains could be achieved by treatment abbreviation to 4 months [6].

Linked to failures in DS-TB therapy, a marked increase has been observed in the incidence of multidrug resistant (MDR-) TB, caused by Mtb bacteria which are resistant to both rifampicin and isoniazid. The estimated number of MDR-TB cases worldwide rose from 250,000 in 2009 to 480,000 in 2015 [1]. Extensively drug-resistant TB, with super-added resistance to injectable second line drugs and fluoroquinolones, comprises 10% of MDR-TB cases. Some of the highest rates are in Eastern Europe where the collapse of health infrastructure during the disintegration of the Soviet Union contributed to difficulties for DS-TB treatment completion [7].

MDR-TB typically requires treatment prolongation to 18–20 months, although the WHO has approved the use of a 9–12-month regimen in some circumstances [8]. The second line drugs used for MDR-TB carry additional toxicities so the need for faster, cleaner therapy is even stronger than in drug susceptible disease [9,10].

The question for clinical pharmacologists is whether detailed interrogation of antibiotic exposure–response relationships will accelerate development of shorter, less toxic therapy for all forms of TB.

**A role for clinical PK–PD studies in achieving these goals**

The clinical trial sequence that resulted in current short course chemotherapy for DS-TB was completed by 1985, and moved directly from Phase I studies of restricted scope to pivotal Phase III trials [2]. Modern PK–PD tools and population pharmacokinetic analysis had not yet been established [8]. Consequently, correlation between drug concentration and therapeutic effect was incompletely evaluated.

Subsequent preclinical experiments have derived summary PK measures, including the maximum drug concentration ($C_{\text{max}}$) or area under the concentration–time curve (AUC), from murine [11,12] or hollow fibre system (HFS) models [13–18] of TB disease. These parameters may be expressed relative to the minimum inhibitory concentration (MIC) of each antibiotic for the infecting Mtb isolate, and related to the rate of bacterial clearance from the model. Results suggest that the efficacy of rifampicin, isoniazid, pyrazinamide and ethambutol is driven by AUC/MIC [13,15–17]. For rifampicin, isoniazid and ethambutol there is also a relationship between efficacy and $C_{\text{ss,max}}$/MIC [15–17]. Data from retrospective meta-analyses contend that the PK–PD indices associated with efficacy in HFS studies are also relevant to clinical disease [18].

Alongside this thought-provoking preclinical PK–PD work sits a growing body of population PK literature revealing up to tenfold interindividual variability in plasma PK indices for first-line antituberculous drugs [19–22]. Studies comparing drug concentrations (particularly the $C_{\text{ss,max}}$ of rifampicin) to a predefined reference range invariably showed antibiotic exposure to be unpredictable and lower than expected [23,24], giving rise to the argument that more detailed clinical PK–PD studies are needed to delineate the contribution of inadequate antibiotic exposure to unfavorable outcomes. Two potential benefits are cited for this approach; improved knowledge of the PK–PD drivers of treatment success may enable early phase clinical trials to predict whether dose escalation of key agents could facilitate treatment shortening in new standardized regimens, and greater understanding of early PK–PD targets linked to long-term cure may permit therapeutic drug monitoring (TDM) and intensification of therapy for patients at high risk of unfavorable outcomes.

**Clinical PK–PD study design**

A generic design to provide an overview of clinical PK–PD studies in TB is outlined in Figure 1. For illustration, only the current 6-month treatment regimen for DS-TB is shown but timescales and regimens may be adapted for MDR-TB. PK–PD studies nested within early phase clinical trials may compare multiple drugs and dose combinations.

Blood sampling for plasma or serum PK assays is generally drawn after daily medications have reached a steady state concentration cycle, typically after at least 14 days of therapy. Intensive PK sampling to establish the AUC for the 24 h after dosing ($\text{AUC}_{0-24}$) is costly and labor intensive because a minimum of six or seven blood samples must be collected at carefully recorded time-points. All specimens should be promptly centrifuged so that plasma or serum can be harvested and frozen at 80°C, prior to batched analysis by HPLC and mass spectrometry. For studies in TB endemic, resource poor countries bioanalysis often requires cold shipment to distant laboratories. Novel approaches to measuring drug exposure or activity in resource-limited
Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes

Review

settings include the use of dried blood spot methods to store and transport samples [25–27], urine colorimetry to detect low rifampicin exposure [28] or co-culturing patients’ Mtb isolate with their plasma on treatment in liquid culture to give an indication of the relative activity of the treatment regimen [29]. For some antituberculous drugs (e.g., amikacin [30], kanamycin [30], moxifloxacin [31] and linezolid [32] in MDR-TB) limited plasma sampling strategies have sought to determine which single time-point measurements best represent more complex PK indices. For other antibiotics (e.g., rifampicin) Bayesian statistical techniques have been deployed to calculate AUCs from sparse sampling strategies (often two to three blood draws) [33]. Potential drawbacks to the Bayesian approach are the need for prior intensive PK data from the same population and reliance on sophisticated computer software [34]. There is also a lack of consensus on optimum sparse sampling time-points for some drugs.

As with preclinical studies, it is recognized that antibiotic PK parameters such as AUC and C\textsubscript{max} should be related to the MIC of each drug for the infecting Mtb isolate. In fact, lack of detailed epidemiological data on MIC distributions for Mtb from most high-incidence TB settings [35,36] makes calculation of AUC/MIC and C\textsubscript{max}/MIC more important for clinical pharmacology studies than for murine or HFS models. Mtb MIC assay plates covering most first and second line antituberculous drugs are available which may expand access to PK–PD testing for TB patients [37], and there have been some practical applications of this approach [38,39]. Correlation of specific genetic mutations in the Mtb genotype with MIC range for some drugs (e.g., gyrA mutations and fluoroquinolone MICS) may also provide more rapid, detailed information than is currently available on the complexity of variable drug susceptibility in the clinical setting [40].

Once PK–PD parameters have been established, selection of appropriate outcome markers is not straightforward. While some studies focus on toxicity or induction of antibiotic resistance, a common purpose is to identify relationships with treatment efficacy. Strengths and weaknesses of TB efficacy end points in regular use by clinical researchers are outlined in Table 1.
The risk of TB relapse after completion of therapy is well recognized, so definitive Phase III clinical trials in DS-TB conventionally use a late efficacy outcome of relapse-free cure 18–24 months after enrollment as their gold standard end point [2, 41]. TDM studies seeking to identify and validate PK–PD targets linked to long-term cure would also ideally be validated against this late outcome. However, trials of this duration, or longer for MDR-TB, are complicated and expensive to complete [10]. From this perspective, clinical PK–PD analyses based on earlier efficacy outcomes in Phase II trials may help to compare novel combinations of drugs and dosages using fewer patients over a shorter timeframe so that only candidate regimens with the greatest efficacy and treatment shortening potential advance to Phase III evaluation.

For this approach, the early outcomes of Phase II studies should predict relapse. Traditionally, for DS-TB patients with pulmonary TB, sputum culture conversion (SCC) from ‘positive’ to ‘negative’ at two months is used to represent treatment efficacy [42]. However, this simple biomarker shows only modest correlation with late outcomes [41, 42]. In recent years, attention has shifted toward weekly sputum sampling to more accurately record the ‘time to culture conversion’ and provide more information on the antibacterial effect of therapy over the entire study period than binary measurement at a single time-point [43, 44]. Modern studies have also seen a gradual move from microbiological treatment monitoring on solid (e.g., Lowenstein-Jensen [LJ]) media to liquid culture (e.g., the mycobacterial growth indicator tube system) because liquid Mtb culture is easier, provides faster results and converts to ‘negative’ later during therapy [45, 46]. It is generally believed that TB relapse is driven by drug-tolerant bacteria which survive despite antibiotic therapy [5]. Therefore, while the PD of distinct bacterial phenotypes in different media are incompletely understood [47], it seems intuitive that liquid culture

Table 1. Treatment efficacy outcomes used in clinical pharmacokinetic-pharmacodynamic studies and clinical trials for tuberculosis.

| Timing of outcome measurement | Outcome measurement | Strengths | Weaknesses |
|------------------------------|---------------------|-----------|------------|
| Late (typically the end of post-treatment follow-up) | Treatment failure or post-treatment relapse | 1. Clinically relevant (target PK–PD parameters for TDM would ideally be validated against this outcome) 2. Gold standard end point for stable cure in Phase III clinical trials | 1. Studies are very long and expensive to conduct 2. Unless careful molecular tests can be undertaken the end point of relapse may be contaminated by TB re-infection in highly endemic settings, especially with high rates of HIV co-infection |
| Early (typically 2 months for DS-TB, may be 24 weeks for MDR-TB) | SCC† at a defined end point | 1. Results are simple to understand and interpret 2. Only requires sputum sampling at two time-points | 1. Only modest correlation with late outcomes 2. Binary data do not use all information (e.g., 2-month results cannot discriminate between patients who are culture negative at 8 weeks, even if one culture converted at 2 weeks and the other at 6 weeks) |
| Time to SCC† | 1. Results are simple to understand and interpret 2. Provides more discriminatory data than SCC | 1. Correlation with late outcomes has not been well validated 2. Weekly sputum sampling required; wider sampling windows reduce the accuracy of the measurement |
| Statistical modeling of bacterial elimination rates from serial quantitative bacteriology data‡ | 1. Provides information on antimicrobial efficacy across the whole sampling time, even on patients who do not convert to negative 2. Allows multiphase patterns of bacterial clearance to be assessed | 1. Correlation of summary parameters from mixed effects modeling with late outcomes has not been well validated 2. Data analysis is computationally complex to perform 3. Results are not always simple to understand and interpret |

†SCC or ‘time to SCC’ data can be generated using solid or liquid culture media; culture conversion is often later in liquid culture systems. ‡Quantitative bacteriology data can be generated from log₁₀ CFU/ml counts on solid media to Time to Positive results in liquid culture systems. DS-TB: Drug-susceptible TB; MDR-TB: Multidrug resistant TB; PK–PD: Pharmacokinetic-pharmacodynamic; SCC: Sputum culture conversion; TDM: Therapeutic drug monitoring.
systems which revive ‘persister’ organisms for longer will provide better surrogates of final outcomes \([48,49]\). Some reports indicate that liquid culture may still fail to revive a proportion of differentially culturable ‘persister’ cells, which only grow from expectorated sputum when media is augmented with exogenous culture filtrate (CF) or resuscitation-promoting factors \([50,51]\). The effect of antibiotic therapy on CF- or resuscitation-promoting factors-dependent bacilli may also be important determinants of TB treatment response, but the relationship between survival of these cells and clinical outcomes has not been evaluated.

Newer methods to monitor TB treatment response and set early outcome measures for PK–PD studies involve use of serial quantitative bacteriology to chart the decline in Mtb bacillary load. In solid media, incubation of homogenized sputum onto on selective agar plates (e.g., Middlebrook 7H10 or 7H11) allows the number of colony forming units (usually expressed in log CFU/ml) in each expectorated patient sample to be counted \([52–54]\). For liquid culture, the time to positivity after inoculation of processed sputum into Mycobacterial Growth Indicator Tubes provides an inverse measure of bacillary load (usually expressed in hours or days) because shorter delay until detection of growth represents higher bacterial burden \([53,55–56]\). Early bactericidal activity studies lasting up to 14 days directly report changes from baseline in log CFU/ml counts or time to positivity \([48,57]\), while studies extending out for 8–12 weeks may deploy statistical modeling techniques to summarize evolving patterns of bacillary clearance over a longer period \([53,58–59]\). Separate elimination rates can be reported for distinct ‘early bacterical’ and ‘sterilizing’ phases of treatment \([43,60]\) and correlation has been described between sterilization phase rate co-efficients and long-term DS-TB outcomes \([53]\). More data are required to validate those relationships.

Presently, no early TB outcome measure convincingly predicts long-term relapse and there is no consensus on which to use. This is demonstrated by the recent failure of three multicenter Phase III trials to shorten drug-susceptible TB treatment from 6 to 4 months by inclusion of a fluoroquinolone \([61–63]\) despite promising results from Phase II clinical studies which used end-points of 2-month SCC \([45,64–65]\), time to culture conversion \([65]\) and bacillary elimination rate \([59]\). Therefore, PK–PD studies relating antibiotic exposure to early outcomes must be aware of the potential limitations to their findings. Future clinical PK–PD analyses may be crucial to development of better treatment response biomarkers.

**Existing clinical PK–PD data**

Table 2 describes published studies which have adopted a PK–PD approach to relate plasma or serum antibiotic exposure to DS-TB treatment efficacy in adults. The collective results are difficult to interpret; some studies report an association between PK variability and treatment response \([66–74]\) while others do not \([75–79]\). No PK–PD markers consistently emerge as potential predictors of efficacy in Phase II clinical trials, or targets to inform TDM strategies in clinical practice.

There are several potential explanations for these mixed results. Pharmacological variability is one of many factors influencing TB treatment \([34]\) and may have varying impact in different settings. The published studies suffer from considerable heterogeneity in design and execution. Most reported antibiotic concentrations at one or two time-points only, reducing the accuracy of C\(_{\text{ave}}\) and AUC calculations. Only one related PK indices to MICs from infecting Mtb isolates \([71]\). A wide range of early and late treatment outcomes measures were used. Treatment failure and relapse are relatively rare events, so smaller cohorts may have been insufficiently powered to demonstrate the effect of antibiotic exposure on unfavorable outcome rates. Finally, the majority were single-arm observational studies which may have diminished their ability to detect relationships with treatment efficacy; for example, most of the interindividual variability in rifampicin concentrations in African settings was at the lower end of the likely exposure–response curve \([23–24,73]\), making it difficult to demonstrate the incremental benefit of higher concentrations on steeper sections of the curve. Standardization of clinical PK–PD study design may provide clarification and facilitate meta-analysis of data from different sites \([81]\).

So far this review has argued that modern PK–PD methods may improve TB treatment but more work is required to translate PK–PD data into practically useful information for researchers and clinicians. The next sections will provide specific examples of ongoing work where PK–PD studies are proving beneficial.

**Ongoing PK–PD work in DS-TB**

DS-TB compromises 95% of TB cases worldwide, with a public health approach required to manage large numbers of patients in low resource settings. Therefore, the main utility of PK–PD work in DS-TB will likely be for development of new, dose-optimized, standard regimens rather than individual patient TDM.

The clearest example of an antibiotic for which dose and exposure–response relationships require re-analysis is rifampicin, a key sterilizing mycobacterial RNA synthesis inhibitor which is critical for achieving relapse-free cure with current DS-TB regimens \([2]\). The current rifampicin dose (10 mg/kg once daily) was selected in the 1960s to facilitate 6-month treatment while minimizing expense \([82]\). Even when costs dropped, toxicity concerns discouraged dose escalation.
Table 2. Summary of pharmacokinetic–pharmacodynamic studies to evaluate antibiotic exposure-treatment efficacy relationships in adults with drug-susceptible tuberculosis.

| Study (year), site | n = | PK sampling | PK parameters | MICs | Outcome measures | Results | Ref. |
|-------------------|-----|-------------|---------------|------|----------------|---------|------|
| Narita (2001), USA | 69  | RH 2, 6 h   | $C_{\text{max}}$ | No   | Late: TB recurrence (presumed relapse) after completion of therapy | No effect of R or H PK on t outcome | [76] |
| Weiner (2003), USA | 133 | Rp, H 1, 2, 5, 24 h | $C_{\text{max}}$, AUC<sub>0-12 h</sub> | No | Late: Composite outcome of treatment failure and relapse | Lower Rp and H AUC<sub>0-12 h</sub> associated with poor outcome | [67] |
| Weiner (2003), USA | 102 | Rp, H 1, 2, 3, 6, 24 h | $C_{\text{max}}$, AUC<sub>0-12 h</sub>, AUC<sub>0-24 h</sub> | No | Late: Composite outcome of treatment failure and relapse Development of rifamycin resistance | Lower Rb AUC<sub>0-24 h</sub> associated with poor outcome and development of antimicrobial resistance Lower H AUC<sub>0-12 h</sub> associated with poor outcome and development of rifamycin resistance | [66] |
| Ribera (2007), Spain | 22  | RH 0.5, 1.5, 2, 3, 4, 6, 8, 12h | $C_{\text{max}}$, AUC<sub>0-24 h</sub> | No | Late: Composite outcome of treatment failure and relapse | No effect of R or H PK on outcome | [79] |
| Chang (2008), Hong Kong | 72  | R only 2, 4 h | $C_{\text{max}}$ | No | Early: 2-month SCC | No effect of R PK on 2-month SCC | [75] |
| Chideya (2009), Botswana | 225 | RHZE 1, 2, 6 h | $C_{\text{max}}$, AUC<sub>0-6 h</sub> | No | Late: Composite outcome of treatment failure or death during therapy | Low $C_{\text{max}}$ for Z (<35 mg/l) associated with poor outcome | [68] |
| Burhan (2013), Indonesia | 167 | RHZE 2hr<sup>1</sup> | $C_{2 h}$ | No | Early: 2-month SCC Additional post-hoc of ≥ 1 positive sputum culture at 4, 8 or 24 weeks | No effect of R, H or E PK on 2-month SCC Low $C_{\text{max}}$ for Z (<35 mg/l) associated with ≥ 1 positive sputum culture at 4, 8 or 24 weeks | [69] |
| Pasipanodya (2013), South Africa | 142 | RHZ 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h | $C_{\text{max}}$, AUC<sub>0-24 h</sub> | No | Early: 2-month SCC Late: Composite outcome of treatment failure, death and relapse | Low $C_{\text{max}}$ for Z (<58.3 mg/l) most strongly associated with reduced 2-month SCC Low AUC<sub>0-24 h</sub> for R (<13 mg.h/l), H (<52 mg.h/l) and Z (<363 mg.h/l) associated with poor long-term outcomes | [70] |
| Chigutsa (2014), South Africa | 154 | RHZE 4-8 samples over 7 h | $C_{\text{max}}$, AUC<sub>0-24 h</sub> | Yes | Early: 8-week sputum bacterial elimination rates<sup>2</sup> | Low $C_{\text{max}}$ for R (<8.2 mg/l) and low AUC<sub>0-24 h</sub>/MIC (<11.3 mg.h/l) associated with slower bacterial elimination | [71] |
| Prahl (2014), Denmark | 32  | RHZE 2h | $C_{2 h}$ | No | Late: Treatment failure | Treatment failure more common with low $C_{2 h}$ of both R (<8 mg/l) and H (<3 mg/l) | [72] |
| Requena-Méndez (2014), Peru | 113 | H 2, 6 h | $C_{2 h}$ | No | Late: Composite outcome of treatment failure and relapse | No effect of H PK on outcome | [78] |

<sup>1</sup>Full PK profile done on a subset of nine patients.

<sup>2</sup>Bacterial elimination rates based on time to event modeling from liquid culture data [80].

<sup>3</sup>Bacterial elimination rates based on mixed effects modeling from solid and liquid culture data [53].

E: Ethambutol; H: Isoniazid; R: Rifampicin; Rp: Rifabutin; Rp: Rifapentine; SCC: Sputum culture conversion; Z: Pyrazinamide. Other abbreviations are as described in the main text.
However, preclinical experiments now suggest that increased rifampicin doses (up to 160 mg/kg/day) may be tolerable and could shorten treatment [16,83]. Mono-therapy studies in humans have demonstrated a steeper fall in bacterial load over 2–14 days with modest dose increases [88,84], and a systematic review of trials including rifampicin doses up to 20 mg/kg showed an association between higher doses and faster SCC [82]. In 2015, a maximum tolerated dose study from Cape Town reported rifampicin dosing up to 35 mg/kg without any limiting toxicity so further work, beginning at 50 mg/kg is planned [85]. Data from Bolivia, Nepal and Uganda corroborate the absence of rifampicin toxicity to 20 mg/kg [86]. The accumulative evidence illustrates a need for new clinical PK–PD studies of high dose rifampicin use.

Intensive PK sampling and analysis from the Cape Town study showed that increased rifampicin doses caused ‘super-proportional’ increases in plasma antibiotic exposure; doubling the dose from 10 to 20 mg/kg was associated with a more than fourfold increase in AUC<sub>0-6h</sub> of rifampicin at day 14 was a better predictor of 14-day bactericidal activity than the dose administered (either in ‘mg’ or weight-adjusted as ‘mg/kg’). A further Multi Arm Multi Stage randomized Phase II trial of several novel treatments for DS-TB (including high-dose rifampicin, moxifloxacin and the experimental compound SQ109) in South Africa and Tanzania has since shown reduced time to sputum culture conversion on liquid media at rifampicin 35 mg/kg across a period of 12 weeks. A 20-patient PK sub-study from that cohort confirmed that rifampicin dose escalation has a ‘super-proportional’ plasma drug exposure effect [87]. Additional PK–PD insights may be gleaned from that dataset, and two more Phase II trials on the efficacy of high dose rifampicin are yet to report (www.clinicaltrials.gov NCT01408914 in Peru and NCT00760149 in Tanzania).

While these data are encouraging, caution is required. Most high dose rifampicin studies excluded HIV co-infected patients or selectively recruited antiretroviral therapy naive individuals with high CD4 counts. Severely immunocompromised HIV patients may be at higher risk of poor drug absorption or adverse events and, as rifampicin is a potent inducer of cytochrome P450 enzymes, higher doses may present an increased challenge in the management of drug–drug interactions. Future clinical PK–PD studies should investigate exposure–response on TB outcomes in this vulnerable population [4]. Furthermore, the notorious unreliability of early PD markers at predicting relapse precludes confidence that rifampicin dose escalation will permit treatment shortening until completion of definitive trials. One Phase III study,
(RIFASHORT, NCT02581527) will start recruiting soon with experimental regimens containing 1200 and 1800 mg of rifampicin (20–30 mg/kg for 60 kg adults). While these data will be valuable it remains to be seen whether this level of dose escalation is enough, particularly as current PK–PD and toxicity data suggest scope to go higher.

PK–PD and dose escalation studies have been undertaken on other rifamycins. Rifapentine produces higher serum concentrations than rifampicin after 10 mg/kg oral dosing and has a longer half-life (15 h, compared with 2–3 h for rifampicin) [34]. Dose increases to 20 mg/kg have been tolerated by healthy volunteers, although the rises in plasma AUC_{0–24} associated with higher doses were not super-proportional [88]. Clinical trials including rifapentine are ongoing (TBTC Study 31, NCT02410772). Rifabutin is sometimes substituted for rifampicin in patients with high drug–drug interaction risks because it is less potent inducer of cytochrome P450 enzymes [89]. Its absorption is variable in HIV patients [90] and toxicities (including leucopenia and uveitis) are concentration dependent. PK–PD is highly recommended and dose increases may be problematic.

Alongside the rifamycins, administration of pyrazinamide for the first 2 months of treatment is key to the sterilizing efficacy of 6-month first-line regimens for DS-TB [2]. Pyrazinamide primarily exerts antituberculous activity in acidic conditions. While early bactericidal activity studies with pyrazinamide demonstrated poor independent bactericidal activity over 14 days, it enhanced the activity of other drugs [48] and some clinical PK–PD studies have shown that reduced exposure is associated with poor late outcomes [68–70]. The population PK profile of pyrazinamide is more stable than rifampicin or isoniazid so predictable plasma concentrations are usually achieved [20,24]. The currently recommended dose is 20–30 mg/kg. Concerns about side-effects of arthralgia and dangerous hepatotoxicity have stifled calls for dose escalation. However, preclinical data suggest that doses up to 60 mg/kg could improve efficacy [13]. A meta-analysis of dose-toxicity relationships in clinical studies reported that, although arthralgia is dose-related, higher dose pyrazinamide did not significantly increase hepatotoxicity and some adverse liver events may be idiosyncratic [91]. Computer simulations suggest that modest pyrazinamide dose increases (up to 40 mg/kg) alongside higher dose rifampicin may accelerate 2-month SCC. Clinical trials with nested PK–PD analyses and toxicity monitoring are planned to test this proposition.

Pharmacological lessons on optimal dosing and drug–drug interactions may yet emerge from the Phase III fluoroquinolone trials which failed to shorten DS-TB therapy [61–63]. A PK sub-study of the OFLO-TUB trial [61] identified that gatifloxacin exposure decreased with rifampicin, isoniazid and pyrazinamide co-administration; and that double-dose gatifloxacin may optimize the bactericidal effect and reduce the probability of resistance [92]. Similarly, drug–drug interactions between rifampicin and isoniazid and moxifloxacin reduce moxifloxacin C_{max} and AUC by 32 and 31%, respectively [93]. Refinement of fluoroquinolone dosing through PK–PD studies may improve outcomes in future trials.

**Ongoing PK–PD work in MDR-TB**

Treatment of MDR-TB is more difficult than DS-TB, with lower treatment success rates and higher incidence of treatment limiting toxicity [9]. Traditional and emerging regimens combine new compounds with old second-line drugs [8] (see Figure 2) and the evidence to support optimal dose combinations is sparse. There is, therefore, considerable scope for clinical PK–PD studies to support optimization of standard drug dosing and TDM. Due to space constraints, two illustrative examples are provided here.

The oxazolidinone, linezolid, has recently been reclassified as a ‘core second line agent’ for MDR-TB treatment [8] (see Figure 2) and may be particularly important for patients with extensive antimicrobial resistance [94–96]. Prolonged therapy is complicated by serious side-effects; bone marrow suppression and peripheral or optic neuropathy are reported in 28% of patients [8]. The routine dose (600 mg orally, twice daily), licensed for treatment of Gram positive non-mycobacterial infections, is currently being formally evaluated alongside bedaquiline and pretomanid in the Nix-TB trial (NCT02333799). To increase tolerability doses of 600 mg daily, 300 mg twice daily and 300 mg once daily are often administered under programmatic conditions [97] and a 600 mg daily dose will be assessed as part of several five drug regimens in the NEXT-TB trial (NCT02454205). A systematic review has tentatively indicated that 300 mg twice daily may retain efficacy while avoiding toxicity but there were difficulties in selecting end points for this retrospective PK–PD analyses [98]. Prospectively collected data are required and recruitment is ongoing to a dose ranging study in South Africa.

Although it is hoped that all-oral treatment for MDR-TB will be available in the future, aminoglycosides (amikacin and kanamycin) are currently integral to all approved regimens. Longer duration, higher doses of these drugs (WHO recommended range: 15–20 mg/kg/day up to a maximum of 1000 mg daily [8]) contributes to favorable outcomes [99] but the therapeutic index is narrow; nephrotoxicity and irreversible otoxicity are common [100]. TDM is
Figure 2. WHO-approved MDR-TB treatment regimens.

*Streptomycin may substitute for other injectable agents in specific scenarios.
‡Thioacetazone must not be used in HIV co-infection.
§This template should be adapted to the antimicrobial resistance profile of the infecting Mtb isolate. If a regimen containing 5 drugs which are likely to be effective cannot be constructed additional group D1-3 agents should be added.
¶Most patients will require a second-line injectable agent for 8 months and total treatment for 20 months but there is scope for modification according to patient response.
#The 9–12 regimen may only be used when resistance to fluoroquinolones and second-line injectable agents has been excluded or is considered unlikely.

**Patients who do not adequately respond to therapy (e.g., sputum smear conversion by 4 months) may have the intensive phase of therapy extended.

Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes

Review

Traditionally recommended to guide aminoglycoside therapy by assaying ‘peak’ and ‘trough’ drug concentrations. However, recent HFS [101] experiments and clinical PK–PD studies in Botswana [102] have suggested $C_{\text{peak}} / \text{MIC}$ and $\text{AUC}_{0-24h} / \text{MIC}$ to be better predictors of treatment efficacy (the clinical studies were based on sputum culture conversion) while cumulative $\text{AUC}_{0-24h} / \text{MIC}$ and duration of therapy correlate best with the risk of ototoxicity [103]. In the Netherlands, individualized aminoglycoside dosing based on $C_{\text{peak}} / \text{MIC}$ resulted in patients receiving an average dose of 6.7 mg/kg [30], which is significantly lower than the WHO recommendation. A retrospective evaluation of the regimen incorporating this approach showed favorable results [104]. Further studies are required but this saliently illustrates how suitable PK–PD thresholds might support safer individualized therapy based on TDM.

Clinical pharmacologists may also help to address further MDR-TB therapeutics issues, including: the role of higher fluoroquinolone doses for patients with resistance mutations conferring modestly elevated MICs [40,105]; the synergistic or antagonistic effects of new antituberculous compounds in combination; and exposure-toxicity aspects of electrocardiographic QTc prolongation by drugs such as fluoroquinolones, clofazimine, bedaquiline and delamanid [106]. There is insufficient space for detailed discussion of these. The remainder of this review will consider emerging challenges and opportunities for the design and conduct of future PK–PD studies.

New assays & outcome measures

Practical aspects of PK sample collection and processing have already been outlined. An additional consideration is that several antibiotics are metabolized to other active compounds after administration (e.g., rifampicin is converted to 25-desacetylrifampicin and pyrazinamide is the pro-drug of pyrazinoic acid [107]). Assays of all active metabolites may be needed to understand the PK–PD characteristics of such agents.

Limitations of sputum culture-based early TB outcome measures have also been discussed. A molecular bacterial load assay has recently been developed which
reports the Mtb bacterial load by quantitation of 16S ribosomal RNA within 72 h of sample processing [108]. This is much faster than the turnaround time for culture. Changes in the molecular bacterial load assay on therapy may allow more efficient TB treatment monitoring [109] and help to develop better outcome measures for TDM and clinical trials. The impact of this technique will depend on validation of data against long-term relapse.

**Interindividual variability & special populations**

Wide interindividual variability in the plasma exposure of some antituberculous antibiotics partly underpins the rationale for clinical PK–PD studies [19–22]. Co-morbidities, concomitant medications, dietary intake and genetic factors regulating drug metabolism all contribute. Greater understanding of the role played by genotype may identify patients at high risk of low exposure, potentially focusing TDM and earlier intervention to improve outcomes.

Isoniazid clearance is driven by N-acetyltransferase 2 enzymes in the liver and small intestine, regulated by the polymorphic NAT2 gene [110]. Single nucleotide polymorphisms in several NAT2 alleles confer fast or slow acetylation phenotypes [110, 111]. Low isoniazid exposure in fast acetylators may be associated with increased risk of unfavorable outcomes and acquired drug resistance while high exposure in slow acetylators may be associated with toxicity [111]. Given the dominant effect of NAT2 genotype on isoniazid exposure, practicing clinicians and researchers should consider categorizing patients by acetylator status.

Genotypic drivers of rifampicin variability are less clear. Biliary excretion occurs after hepatocellular uptake, primarily mediated by organic anion-transporting polypeptide 1B1 coded for by the gene SLCO1B1 [112]. Recent reports from South Africa and Uganda suggest that single nucleotide polymorphisms in SLCO1B1 are more common in African patients and associated with up to 28% reduction in rifampicin AUC_0–24hr in homozygotes [112, 113]. However, given extensive population diversity in SLCO1B1 polymorphism carriage [114], these findings have not been replicated in India, Tanzania or Malawi [115, 116, 117]. Future PK–PD studies should investigate further.

Some PK variability is associated with physiologically distinct, but previously neglected populations where a strong case exists for separate PK–PD studies and clinical trials. Foremost among these are children. Previously, pediatric dosing and duration of first-line TB therapy were extrapolated on a mg/kg basis from adult studies, but this resulted in lower plasma concentrations than the adult population. In 2010, the WHO recommended increased doses of all four first-line TB drugs [118]. Few PK studies have been performed to assess the impact of these adjustments. Emerging data from South Africa and Malawi indicate that rifampicin may be associated with toxicity [111]. Given the dominant effect of NAT2 genotype on isoniazid exposure, practicing clinicians and researchers should consider categorizing patients by acetylator status.

**Table 3. Pharmacokinetic sampling sites.**

| Sampling site | Advantages                                                                 | Disadvantages                                                                 |
|---------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Peripheral blood (plasma or serum) | Ease of repeat sampling | Far from site of infection, Unclear relationship with outcome, Wide interindividual variability |
| Bronchoalveolar lavage | ‘Near infection’ samples - alveolar macrophages and epithelial lining fluid, Can be paired with rich plasma/serum sampling, Models of intrapulmonary exposure can be developed using population modeling techniques | Invasive procedure, Single time point sampling, Sample from alveoli and bronchioles rather than within granuloma, Drug loss due to efflux when sampling, Differential penetration depending on inflamed/noninflamed lung/different lobes, Sampling retrieves mixture of macrophages, T-lymphocytes and epithelial cells |
| Lung explant studies | Can assess spatial drug penetration, Can combine with spatial data on drug susceptibility profile and MIC | Only possible in patients requiring lung resection (either severe disease or a sub-set of MDR-TB patients), Single time point drug concentrations |
| Cerebrospinal fluid (for TB meningitis) | Accessible, Can be paired with rich plasma sampling, Models of CSF drug exposure can be developed using population modeling techniques | Invasive procedure, Single time point sampling, Traumatic tap will contaminate samples |

CSF: Cerebrospinal fluid; MDR: Multidrug resistant; MIC: Minimum inhibitory concentration.
exposures remain low [119,120]. A cohort evaluation of 161 Indian children aged 1–15 has suggested that a low \( C_{\text{max}} \) for rifampicin (<3.01 mg/l) or pyrazinamide (<38.01 mg/l) predicted late outcomes of treatment failure or death [121]. There is almost no clinical PK–PD information on second-line drugs for MDR-TB in pediatric populations.

Although the evidence is debatable, patients with HIV co-infection [23,122] diabetes mellitus [123–125] and pregnant women [126] may also have unusual PK–PD profiles, necessitating detailed sub-studies to clarify the role of TDM and altered antibiotic dosing. Systematic use of early TDM with dose correction in diabetic patients may shorten time to sputum culture conversion [127].

**PK–PD at the site of disease**

All the PK–PD data described hitherto report antibiotic exposure in peripheral blood, but TB is not primarily a bloodstream infection. In pulmonary TB, Mtb exists within discrete microenvironments: intracellular organisms within granuloma macrophages; free extracellular organisms in caseum, cavities and airways; and in apparently ‘normal’ interstitial lung tissue [128]. It is improbable that unbound drug passively equilibrates between blood and all tissue compartments so investigation of relationships between peripheral blood and lesion PK–PD is important. Advantages and disadvantages of clinically focused methods for this are outlined in Table 3.

One novel approach is to generate spatial drug penetration information by performing matrix-assisted laser desorption/ionization mass spectrometry on dissected tissue from patients undergoing lung resection surgery for antibiotic-refractory disease [5,129]. Early results suggest excellent rifampicin and pyrazinamide penetration into the central necrotic caseum of TB granulomas but peripheral intracellular accumulation of moxifloxacin [130]. These data may explain why rifampicin and pyrazinamide are critical DS-TB sterilizing agents but treatment shortening trials with moxifloxacin were unsuccessful [62,63]. However, an alternative approach using microdialysis on \( ex vivo \) pulmonary cavities from patients with MDR-TB shows excellent penetration of levofloxacin into cavity walls, and good correlation between serum and cavity fluoroquinolone concentrations [131]. From a PD perspective, lung resection studies have shown differing drug susceptibility patterns in Mtb isolates from different pulmonary cavities of the same patient [132,133] and mathematical models suggest that bacilli in compartments with low antibiotic penetration develop higher MICs. Overall, such advanced PK–PD work on resected lung tissue is beginning to generate very detailed information on the extent and consequences of antibiotic exposure at the site of infection. A disadvantage of these experiments is that they are only possible on a small sub-set of unusual and highly selected patients with very severe TB and particularly distorted lung anatomy.

An alternative means of ‘near infection’ PK sampling is the use of broncho-alveolar (BAL) lavage to sample epithelial lining fluid (ELF) and alveolar macrophages. Given the invasive nature of this procedure, all previous BAL studies were conducted on small numbers of healthy volunteers with single time-point sampling. Results show extensive variability in the pulmonary penetration of first-line drugs. In ELF, isoniazid concentrations appeared low in relation to likely MICs for clinical Mtb isolates and projected rifampicin AUC/MIC measurements appeared insufficient to suppress resistance in a high proportion of subjects [134–138]. Alveolar macrophage/ELF concentration ratios ranged from 0.1 to >20, with rifampicin, ethambutol and fluoroquinolones concentrating most effectively within cells [5,136,139]. Difficulties for BAL-based studies are the potential clinical hazard and infection control risks associated with performing bronchoscopies on sick patients and the need to collect luminal specimens rather than those directly from granulomas. An ongoing clinical PK–PD cohort of TB patients with BAL sampling in Malawi will provide new information.

Fifteen to twenty percent of TB cases are extra-pulmonary. Penetration of antibiotics to other infection sites may differ from the lungs. Specific PK–PD studies have been completed in TB meningitis, where treatment regimens derived from data on pulmonary TB do not account for the extent of drug penetration across the blood–brain barrier. Isoniazid, pyrazinamide and the fluoroquinolones reach cerebrospinal fluid (CSF) in high concentrations, whereas streptomycin does not [140]. Interestingly, for fluoroquinolones both ‘low’ and ‘high’ CSF drug exposures are associated with poorer outcomes, and intermediate exposures are associated with less death and disability [141]. It is likely that more extensive breakdown of the blood–brain barrier with severe disease explains the link between higher drug exposure and poorer outcomes.

CSF rifampicin exposure is lower than plasma [142]. A Phase II clinical trial of rifampicin (13 mg/kg) intravenously alongside moxifloxacin, isoniazid, pyrazinamide and corticosteroids in Indonesia identified a survival benefit from higher CSF rifampicin concentrations, with substantially lower 6-month mortality in patients receiving the higher dose [143,144]. Conversely, a Phase II trial in Vietnam, using oral rifampicin (15 mg/kg) and levofloxacin (20 mg/kg) did not improve survival [145]. More studies are needed to
determine whether rifampicin dose escalation, perhaps allied to intravenous administration, does improve outcomes [85,146].

**Conclusion**

Current treatment regimens for DS-TB and MDR-TB are not based on a detailed understanding of exposure–response relationships for the antibiotic combinations which are used. Development of shorter, less toxic therapeutic strategies for all forms of TB is a key global research priority. Preclinical studies in animals and HFS have indicated that clinical PK–PD studies may contribute toward achievement of this goal by helping to optimize dosing for new standard regimens and, in some cases, by providing an evidence base for TDM to guide the management of individual patients.

**Future perspective**

After many barren years in TB drug development, intensified efforts to accelerate the evaluation combinations of existing antibiotics alongside novel compounds are beginning to bear fruit and there are real opportunities to improve treatment outcomes. PK–PD science will make an important contribution to this endeavor, increasing the chance of success, especially if insights from preclinical HFS work can be validated and extended by clinical PK–PD studies.

The greatest impact may be obtained at the level of Phase II clinical trials. If analysis of PK–PD parameters in relation to early treatment outcomes (measured ~8 weeks into treatment for DS-TB) could predict the long-term risk of eventual relapse, more efficacious regimens might advance more quickly to Phase III evaluation. This would accelerate progress toward shorter therapy with attendant benefits for all patients. However, early treatment outcomes are currently poor surrogates of final end points and it remains to be seen whether new monitoring tools will help overcome this obstacle. Standardization of PK–PD study design and meta-analyses of larger total datasets may pave the way forward [81].

TDM may be of value in patients from groups with unpredictable PK characteristics (e.g., in the presence of HIV infection, potential drug–drug interactions or renal/hepatic dysfunction). It may also improve the treatment of MDR-TB where several drugs have a narrow therapeutic index. For this approach to be effectively exploited, plasma concentration ranges associated with safe and successful TB treatment need to be better defined. That is currently problematic, given the scarcity of PK–PD datasets for second-line antituberculous drugs but this knowledge gap provides fertile ground for future research. A large prospective cohort enrolling in Bangladesh, Tanzania, Uganda and Siberia may help to address this knowledge gap for some special population groups (NIH U01 ICIDR AI119954) but additional studies are needed.

Emerging and overdue priority areas for TB pharmacologists are specific design of antibiotic regimens

**Executive summary**

**Background & rationale for clinical pharmacokinetic-pharmacodynamic studies of TB treatment**

- Shorter, less toxic treatment regimens are urgently required for all forms of TB.
- Clinical pharmacokinetic-pharmacodynamic (PK–PD) studies may help improve the conduct of Phase II clinical trials, and facilitate therapeutic drug monitoring for some drugs.

**Existing studies & their limitations**

- Results are variable but some show associations between low plasma $C_{\text{max}}$ or AUC measurement for first-line drugs and treatment response.
- Inconsistency in study design and selection of outcome measures contributes to difficulty in collective interpretation of prior data.

**Ongoing PK–PD work in drug-susceptible TB**

- Increased rifampicin doses for patients with pulmonary DS-TB may be associated with super-proportional increases in the AUC$_{0-24h}$ and faster sputum sterilization.
- PK–PD modeling suggests that higher dose pyrazinamide may be possible.
- Fluoroquinolones doses may require to be increased to account for the effect of drug–drug interactions.

**Ongoing PK–PD work in multidrug resistant TB**

- The optimal dose of linezolid, to maximize efficacy while minimizing toxicity, is under evaluation.
- Therapeutic drug monitoring for aminoglycosides may be better targeted against $C_{\text{max}}$/MIC and AUC$_{0-24h}$/MIC than traditional ‘peak’ and ‘trough’ measurements.
- Many additional questions require attention, including the efficacy and toxicity of novel drug combinations (e.g., bedaquiline and delamanid).

**Challenges for future studies**

- PK–PD study design should consider incorporating assays of active drug metabolites and free drug fractions. New treatment monitoring tools should be considered when selecting early outcome measures.
- PK–PD studies and clinical trials should be specifically designed for children and other special populations.
- PK–PD analyses at the site of infection may provide additional insights into the factors driving treatment efficacy.
for children and patients with extra-pulmonary TB. Frameworks are being developed for pediatric-focused HFS-based PK–PD studies [47] and it is to be hoped that clinical studies will follow.

Overall, despite numerous unanswered questions and technical challenges, the landscape has rarely been more optimistic in TB therapeutics. Judicious evaluation of novel antibiotic combinations carries real potential for better, safer and shorter treatment for all patient groups. Clinical PK–PD studies have an important role to play in achieving that goal.

Financial & competing interests disclosure
Wellcome Trust (Clinical PhD Fellowship awarded to A McCallum). Grant Number: 105392/B/14/Z. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
Papers of special note have been highlighted as:
• of interest; •• of considerable interest
1 World Health Organization. Global Tuberculosis Report 2016. www.who.int/tb/publications/global_report/en/
2 Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3(10 Suppl. 2), S231–S279 (1999).
3 Raviglione MC, Harries AD, Msika R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS 11(Suppl. B), S115–S123 (1997).
4 Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther. Drug Monit. 37(1), 22–32 (2015).
5 Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12(3), 159–167 (2014).
6 Salahon JA, Lloyd-Smith JO, Getz WM et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 3(8), e273 (2006).
7 Toungoussova OS, Bjune G, Caugant DA. Epidemic of tuberculosis in the former Soviet Union: social and biological reasons. Tuberculosis 86(1), 1–10 (2006).
8 World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. www.who.int/tb/areas-of-work/drug-resistant-tb/MDRTBGuidelines2016.pdf
9 Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans. R. Soc. Trop. Med. Hyg. 110(3), 163–172 (2016).
10 Sloan DJ, Davies GR, Khoo SH. New drugs and treatment regimens. Curr. Respir. Med. Rev. 9(3), 200–210 (2013).
11 Jayaram R, Sandhil RK, Gaonkar S et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48(8), 2951–2957 (2004).
12 Jayaram R, Gaonkar S, Kaur P et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47(7), 2118–2124 (2003).
13 Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53(8), 3197–3204 (2009).
14 Pasipanodya JG, Nuernberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin. Infect. Dis. 61(Suppl. 1), S10–S17 (2015).
15 Gumbo T, Louie A, Liu W et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51(7), 2329–2336 (2007).
16 Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51(11), 3781–3788 (2007).
17 Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Eflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201(8), 1225–1231 (2010).
18 Gumbo T, Pasipanodya JG, Nuernberger E, Romero K, Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin. Infect. Dis. 61(Suppl. 1), S18–S24 (2015).
19 References 13–18 represent an emerging body of work on pharmacokinetic–pharmacodynamic (PK–PD)-based...
hollow fibre system experiments of tuberculosis (TB) therapy, which help to inform the design of prospective clinical studies

19 Wilkins JJ, Langdon G, Mclleron H, Pillai G, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br. J. Clin. Pharmacol. 72(1), 51–62 (2011).

20 Wilkins JJ, Langdon G, Mclleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62(9), 727–735 (2006).

21 Wilkins JJ, Savic RM, Karlsson MO et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52(6), 2138–2148 (2008).

22 Jonsson S, Davids A, Wilkins J et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob. Agents Chemother. 55(9), 4230–4237 (2011).

23 Mclleron H, Wash P, Burger A, Norman J, Folli PL, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50(4), 1170–1177 (2006).

• Illustrates the interindividual variability of all first-line anti-TB drugs, and evaluates some of the factors responsible for this.

24 Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antitymcobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41(4), 461–469 (2005).

25 Lee K, Jun S-H, Han M et al. Multiplex assay of second-line anti-tuberculosis drugs in dried blood spots using ultra-performance liquid chromatography-tandem mass spectrometry. Ann. Lab. Med. 36(5), 489–493 (2016).

26 Vu DH, Koster RA, Bolhuis MS et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta 121, 9–17 (2014).

27 Vu DH, Bolhuis MS, Koster RA et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56(11), 5758–5763 (2012).

28 Zentner I, Schlecht HP, Khenschouvan L et al. Urine colorimetry to detect low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect. Dis. 16, 242 (2016).

29 Heysell SK, Mtabho C, Mpagama S et al. Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob. Agents Chemother. 55(12), 5819–5825 (2011).

30 Dijkstra JA, van Altena R, Akkerman OW et al. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Int. J. Antimicrob. Agents 46(3), 332–337 (2015).

31 Pranger AD, Kosterink JG, van Altena R et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther. Drug Monit. 33(3), 350–354 (2011).

32 Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Poost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther. Drug Monitor. 32(1), 97–101 (2010).

33 Sturkenboom MG, Mulder LW, de Jager A et al. Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of Rifampin in patients with tuberculosis. Antimicrob. Agents Chemother. 59(8), 4907–4913 (2015).

34 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74(8), 839–854 (2014).

35 Pasapanodya J, Srivastava S, Gumto T. New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 56(10), 5428 (2012).

36 Schon T, Jureen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64(4), 786–793 (2009).

37 Lee J, Armstrong DT, Sengooba W et al. Sensitivity MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob. Agents Chemother. 58(1), 11–18 (2014).

38 Heysell SK, Ahmed S, Ferdous SS et al. Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS ONE 10(2), e0116795 (2015).

39 Mpagama SG, Houpt ER, Sroupp S et al. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect. Dis. 13, 432 (2013).

40 Fongalda S, Banu S, Pholwat S et al. Comparison of TaqMan® Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB. Int. J. Tuberc. Lung Dis. 20(8), 1105–1112 (2016).

41 Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS ONE 8(5), e63840 (2013).

42 Horne DJ, Royce SE, Gooze L et al. Sputum monitoring during tuberculosis treatment for predicting outcome: a systematic review and meta-analysis. Lancet Infect. Dis. 10(6), 387–394 (2010).

43 Davies GR. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis 90(3), 171–176 (2010).

44 Holtz TH, Sternberg M, Kammerer S et al. Time to spumur culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann. Int. Med. 144(9), 650–659 (2006).
Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes

References 61–63 describe three important Phase III clinical trials that attempted to shorten DS-TB treatment by inclusion of fluoroquinolones. All three trials failed, illustrating the difficulty in treatment shortening and the need for better early measures of treatment outcome for Phase II studies. PK–PD studies have suggested that high doses of fluoroquinolones may be needed to overcome drug–drug interactions in combination with first-line antibiotics.

• References 61–63 describe three important Phase III clinical trials that attempted to shorten DS-TB treatment by inclusion of fluoroquinolones. All three trials failed, illustrating the difficulty in treatment shortening and the need for better early measures of treatment outcome for Phase II studies. PK–PD studies have suggested that high doses of fluoroquinolones may be needed to overcome drug–drug interactions in combination with first-line antibiotics.

45 Dorman SE, Johnson JL, Goldberg S et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. *Am. J. Respir. Crit. Care Med.* 180(3), 273–280 (2009).

46 Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsai VC. Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. *Int. J. Tuberc. Lung Dis.* 7(6), 569–574 (2003).

47 Barr DA, Kamdolizi M, Nishihara Y et al. Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB. *Tuberculosis* 98, 110–115 (2016).

48 Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. *Am. J. Respir. Crit. Care Med.* 167(10), 1348–1354 (2003).

49 Friedrich SO, Rachow A, Saathoff E et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. *Lancet Respir. Med.* 1(6), 462–470 (2013).

50 Chengalroyen MD, Beukes GM, Gordhan BG et al. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. *Am. J. Respir. Crit. Care Med.* 194(12), 1532–1540 (2016).

51 Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. *Am. J. Respir. Crit. Care Med.* 181(2), 174–180 (2010).

52 Sloan DJ, Corbett EL, Butterworth AE et al. Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. *J. Clin. Microbiol.* 50(7), 2315–2320 (2012).

53 Sloan DJ, Mwandumba HC, Garton NJ et al. Pharmacodynamic modelling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. *Clin. Infect. Dis.* 61(1), 1–8 (2015).

54 Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. *Am. Rev. Respir. Dis.* 121(6), 939–949 (1980).

55 Diaco AH, Maritz JS, Venter A et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. *Eur. J. Clin. Microbiol. Infect. Dis.* 29(12), 1561–1565 (2010).

56 Pfeiffer C, Carroll NM, Beyers N et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. *Int. J. Tuberc. Lung Dis.* 12(7), 792–798 (2008).

57 Siegel FA, Donald PR, Odhiambo J et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. *J. Antimicrob. Chemother.* 45(6), 859–870 (2000).

58 Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. *Antimicrob. Agents Chemother.* 50(9), 3154–3156 (2006).

59 Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. *Int. J. Tuberc. Lung Dis.* 12(2), 128–138 (2008).

60 Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. *Open Infec. Dis. J.* 2, 59–76 (2008).

61 Merle CS, Fielding K, Sow OB et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. *N. Engl. J. Med.* 371(17), 1588–1598 (2014).

62 Jindani A, Harrison TS, Nunn AJ et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. *N. Engl. J. Med.* 371(17), 1599–1608 (2014).

63 Gillespie SH, Crook AM, McHugh TD et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. *N. Engl. J. Med.* 371(17), 1577–1587 (2014).

• References 61–63 describe three important Phase III clinical trials that attempted to shorten DS-TB treatment by inclusion of fluoroquinolones. All three trials failed, illustrating the difficulty in treatment shortening and the need for better early measures of treatment outcome for Phase II studies. PK–PD studies have suggested that high doses of fluoroquinolones may be needed to overcome drug–drug interactions in combination with first-line antibiotics.

64 Burman WJ, Goldberg S, Johnson JL et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. *Am. J. Respir. Crit. Care Med.* 174(3), 331–338 (2006).

65 Conde MB, Efron A, Loredo C et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled Phase II trial. *Lancet* 373(9670), 1183–1189 (2009).

66 Weiner M, Benator D, Burman W et al. Association between acquired rifampicin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. *Clin. Infect. Dis.* 40(10), 1481–1491 (2005).

67 Weiner M, Burman W, Vernon A et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. *Am. J. Respir. Crit. Care Med.* 167(10), 1341–1347 (2003).

68 Chideya S, Winston CA, Peloquin CA et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. *Clin. Infect. Dis.* 48(12), 1685–1694 (2009).

• A clinical PK–PD study suggesting that inadequate pyrazinamide exposure may be associated with unfavorable outcomes.

69 Burhan E, Ruesen C, Ruslami R et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. *Antimicrob. Agents Chemother.* 57(8), 3614–3619 (2013).

70 Pasipanodya JG, Meilleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. *J. Infect. Dis.* 208(9), 1464–1473 (2013).
• A clinical PK–PD study suggesting that inadequate rifampicin, isoniazid and pyrazinamide exposure may be associated with unfavorable outcomes.

71 Chigutsa E, Pasipanodya JG, Visser ME et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 59(1), 38–45 (2015).

• A clinical PK–PD study suggesting that rifampicin exposure may be associated with unfavorable outcomes.

72 Prahl JB, Johansen IS, Cohen AS, Frimodt-Møller N, Andersen AB. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J. Antimicrob. Chemother. 69(10), 2841–2847 (2014).

Sloan DJ, Schipani A, Waterhouse D et al. Pharmacokinetic variability in TB therapy: associations with HIV and effect on outcome. Presented at: Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 March 2014 (Abstract 993).

74 Mah A, Kharrat H, Ahmed R et al. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. Int. J. Tuberc. Lung Dis. 19(2), 210–215 (2015).

75 Chang KC, Leung CC, Yew WW et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis. 27(6), 467–472 (2008).

76 Narita M, Hisada M, Thimmappa B et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin. Infect. Dis. 52(3), 515–517 (2001).

77 Park JS, Lee JY, Lee YJ et al. Serum levels of antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob. Agents Chemother. 60(1), 92–98 (2015).

78 Requena-Mendez A, Davies G, Waterhouse D et al. Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob. Agents Chemother. 58(12), 7164–7170 (2014).

79 Ribera E, Azua C, Lopez RM et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J. Antimicrob. Chemother. 59(4), 690–697 (2007).

80 Chigutsa E, Patel K, Denti P et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob. Agents Chemother. 57(2), 789–795 (2013).

81 Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J. Infect. Dis. 211(Suppl 3), S96–S106 (2015).

82 Steingart KR, Joblud S, Robsky K et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis. 15(3), 305–316 (2011).

83 de Steenwinkel JE, Aarnoutse RE, de Knegt GJ et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am. J. Respir. Crit. Care Med. 187(10), 1127–1134 (2013).

84 Diacon AH, Patientia RF, Venter A et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51(8), 2994–2996 (2007).

85 Boeree MJ, Diacon AH, Dawson R et al. A dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 191(9), 1058–1065 (2015).

**A Phase II rifampicin dose escalation trial with a PK sub-study showing that rifampicin doses up to 35 mg/kg are tolerable and associated with super-proportional increases in plasma rifampicin exposure. The 35 mg/kg dose was also associated with slightly faster bacterial clearance from sputum.**

86 Jindani A, Borgulya G, de Patino IW et al. A randomised Phase II trial to evaluate the toxicity of high-dose rifapentine to treat pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 20(6), 832–838 (2016).

87 Boeree MJ, Heinrich N, Aarnoutse R et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect. Dis. 17, 39–49 (2017).

**A Phase II study with a PK sub-study corroborating the benefits of higher dose rifampicin indicated in Reference 97.**

88 Dooley KE, Bliven-Sizemore EE, Weiner M et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91(5), 881–888 (2012).

89 Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 28(3), 419–429; quiz 430 (1999).

90 Boulanger C, Hollender E, Farrell K et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49(9), 1305–1311 (2009).

91 Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob. Agents Chemother. 54(7), 2847–2854 (2010).

92 Smythe W, Merle CS, Rustomjee R et al. Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. Antimicrob. Agents Chemother. 57(9), 4164–4171 (2013).

93 Nijland HM, Ruslami R, Suroto AJ et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45(8), 1001–1007 (2007).
Importance of clinical PK–PD studies in unraveling the determinants of early & late TB outcomes  

Review

94 Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB—final study outcomes. N. Engl. J. Med. 373(3), 290–291 (2015).
95 Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367(16), 1508–1518 (2012).
96 Tako S, Yao L, Hao X et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur. Respir. J. 45(1), 161–170 (2015).
97 Koh WJ, Kang YR, Jeon K et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 67(6), 1503–1507 (2012).
98 Millard J, Pertinez H, Bonnett L et al. Low dose linezolid therapy attains putative pharmacokinetic/pharmacodynamic efficacy and toxicity targets in tuberculosis: meta-analysis and Monte Carlo simulation. Presented at: 47th Union World Conference on Lung Health, Liverpool, UK, 26–29 October 2016 (Abstract EP-102–27).
99 Modongo C, Sobota RS, Keseneogile B et al. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect. Dis. 14, 542 (2014).
100 de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 6(7), 622–627 (2002).
101 Srivastava S, Modongo C, Siyambalapityage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T. Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. Antimicrob. Agents Chemother. 60(10), 5922–5927 (2016).
102 Modongo C, Pasipanodya JG, Magazi BT et al. Artificial intelligence and amikacin exposures predictive of outcomes in multidrug-resistant tuberculosis patients. Antimicrob. Agents Chemother. 60(10), 5928–5932 (2016).
103 Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of otootoxicity in multidrug-resistant tuberculosis patients. Antimicrob. Agents Chemother. 59(10), 6337–6343 (2015).
104 van Altena R, de Vries G, Haar CH et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int. J. Tuberc. Lung Dis. 19(4), 406–412 (2015).
105 Poissy J, Aubry A, Fernandez C et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54(11), 4765–4771 (2010).
106 Harauz E, Cox H, Rich M, Mintick CD, Zimetbaum P, Furin J. QT prolongation and treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 19(4), 385–391 (2015).
107 Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7(1), 6–21 (2003).
108 Honeyborne I, McHugh TD, Phillips PP et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J. Clin. Microbiol. 49(11), 3905–3911 (2011).
109 Honeyborne I, Mafuya B, Phillips PP et al. The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J. Clin. Microbiol. 52(8), 3064–3067 (2014).
110 Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49(5), 1733–1738 (2005).
111 Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55(2), 169–177 (2012).
112 Chigutsa E, Visser ME, Swart EC et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob. Agents Chemother. 59(5), 4122–4127 (2011).
113 Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS. Low rifampicin concentrations in tuberculosis patients with HIV infection. J. Infect. Dev. Ctries 8(8), 987–993 (2014).
114 Akllu E, Habtewold A, Ngaimisi E et al. SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: relevance for African and worldwide precision medicine. Omics 20(9), 538–545 (2016).
115 Ramesh K, Hemamth Kumar AK, Kannan T et al. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population. Int. J. Tuberc. Lung Dis. 20(9), 1231–1235 (2016).
116 Jeremiah K, Denti P, Chigutsa E et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob. Agents Chemother. 58(6), 3468–3474 (2014).
117 Sloan DJ, McCallum AD, Schipani A et al. Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother. pii: AAC.00210-17 doi: 10.1128/AAC.00210-17 (2017) (Epub ahead of print).
118 World Health Organization. Rapid Advice: Treatment Of Tuberculosis In Children. World Health Organization, Geneva (2010).
119 Bekker A, Schaaf HS, Draper HR et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob. Agents Chemother. 60(4), 2171–2179 (2016).
120 Schipani A, Pertinez H, Mlota R et al. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. Br. J. Clin. Pharmacol. 81(4), 679–687 (2015).
121 Swaminathan S, Pasipanodya JG, Ramachandran G et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin. Infect. Dis. 63(Suppl. 3), S63–S74 (2016).
An interesting study using innovative methods to illustrate spacial variability in the penetration of several antituberculosis antibiotics to different sub-compartments of TB granulomas.

- McIlerson H, Rustomjee R, Vahedi M et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob. Agents Chemother. 56(6), 3232–3238 (2012).
- Conte JE, Golden JA, Kipps JE, Lin ET, Zurliended E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43(6), 395–404 (2004).
- Conte JE Jr, Golden JA, Kipps J, Lin ET, Zurliended E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob. Agents Chemother. 45(10), 2891–2896 (2001).
- Conte JE, Golden JA, McQuitty M et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob. Agents Chemother. 46(8), 2358–2364 (2002).
- Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurliended E. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43(6), 1329–1333 (1999).
- Prideaux B, Via LE, Zimmerman MD et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21(10), 1223–1227 (2015).
- Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 90(5), 279–292 (2010).
- McIlerson H, Rustomjee R, Vahedi M et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob. Agents Chemother. 56(6), 3232–3238 (2012).
- Conte JE, Golden JA, Kipps JE, Lin ET, Zurliended E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43(6), 395–404 (2004).
- Conte JE Jr, Golden JA, Kipps J, Lin ET, Zurliended E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob. Agents Chemother. 45(10), 2891–2896 (2001).
- Conte JE, Golden JA, McQuitty M et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob. Agents Chemother. 46(8), 2358–2364 (2002).
- Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurliended E. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43(6), 1329–1333 (1999).
- Prideaux B, Via LE, Zimmerman MD et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21(10), 1223–1227 (2015).
- Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 90(5), 279–292 (2010).
- Thwaites GE, Bhavnani SM, Chau TT et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob. Agents Chemother. 55(7), 3244–3253 (2011).
- Pouplin T, Bang ND, Toi PV et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect. Dis. 16(1), 144 (2016).
- Te Brake L, Dian S, Ganiem AR et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int. J. Antimicrob. Agents 45(5), 496–503 (2015).
- Konton V, Dixon A, S, Sen R et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled Phase II trial. Lancet Infect. Dis. 13(1), 27–35 (2013).
- Heemskerk AD, Bang ND, Mai NT et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N. Engl. J. Med. 374(2), 124–134 (2016).
- Yunivita V, Dian S, Ganiem AR et al. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int. J. Antimicrob. Agents 48(4), 415–421 (2016).
- Gumbo T, Makhene MK, Seddon JA. Partnerships to design novel regimens to treat childhood tuberculosis, Sui Generis: the road ahead. Clin. Infect. Dis. 63(Suppl. 3), S110–S115 (2016).